Literature DB >> 2083224

[Biological properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma].

M Sakayori1, S Nozawa, Y Udagawa, K Chin, S G Lee, T Sakuma, R Iizuka, Y Wada, S Yoshida, Y Takeda.   

Abstract

Two morphological different cell lines (RMUG-S and RMUG-L) have been established from a human ovarian mucinous cystadenocarcinoma. CA-125 and CEA were demonstrated in the patient's serum. PAS, Alcian blue and mucicarmine positive substances were observed in the original tumor and two cultured cells. The modal chromosomal numbers of RMUG-S and RMUG-L were stable in the hypodiploid and hyper-triploid ranges, respectively. Radioimmunoassay and immunocytochemical staining revealed that RMUG-S and RMUG-L mainly produced CA-125 and CEA, respectively. In CBA nude mouse, RMUG-S and RMUG-L cells mainly produced poorly-differentiated adenocarcinoma, but in mucinous cystadenocarcinoma was detected in part of the RMUG-L tumor.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2083224

Source DB:  PubMed          Journal:  Hum Cell        ISSN： 0914-7470            Impact factor:   4.174


  9 in total

1.  Targeting SRC in mucinous ovarian carcinoma.

Authors:  Koji Matsuo; Masato Nishimura; Justin N Bottsford-Miller; Jie Huang; Kakajan Komurov; Guillermo N Armaiz-Pena; Mian M K Shahzad; Rebecca L Stone; Ju Won Roh; Angela M Sanguino; Chunhua Lu; Dwight D Im; Neil B Rosenshien; Atsuko Sakakibara; Tadayoshi Nagano; Masato Yamasaki; Takayuki Enomoto; Tadashi Kimura; Prahlad T Ram; Kathleen M Schmeler; Gary E Gallick; Kwong K Wong; Michael Frumovitz; Anil K Sood
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

2.  Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.

Authors:  Sojiro Sato; Yoichi Kobayashi; Yoshiaki Okuma; Haruhiro Kondo; Yosuke Kanishi; Kaoru Saito; Kazusige Kiguchi
Journal:  Hum Cell       Date:  2002-09       Impact factor: 4.174

3.  The promise and challenge of ovarian cancer models.

Authors:  Noor Hasan; Anders W Ohman; Daniela M Dinulescu
Journal:  Transl Cancer Res       Date:  2015-02       Impact factor: 1.241

4.  PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.

Authors:  Takeshi Hisamatsu; Michael McGuire; Sherry Y Wu; Rajesha Rupaimoole; Sunila Pradeep; Emine Bayraktar; Kyunghee Noh; Wei Hu; Jean M Hansen; Yasmin Lyons; Kshipra M Gharpure; Archana S Nagaraja; Lingegowda S Mangala; Takashi Mitamura; Cristian Rodriguez-Aguayo; Young Gyu Eun; Johnathon Rose; Geoffrey Bartholomeusz; Cristina Ivan; Ju-Seog Lee; Koji Matsuo; Michael Frumovitz; Kwong K Wong; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2018-10-10       Impact factor: 6.261

5.  Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.

Authors:  Mohammed Habis; Kristen Wroblewski; Michael Bradaric; Nadia Ismail; S Diane Yamada; Lacey Litchfield; Ernst Lengyel; Iris L Romero
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II).

Authors:  S Nozawa; M Yajima; H Sasaki; K Tsukazaki; D Aoki; M Sakayori; Y Udagawa; T Kobayashi; I Sato; S Furusako
Journal:  Jpn J Cancer Res       Date:  1991-07

7.  High expression of uridine diphosphate-galactose: Lc3Cer beta 1-3 galactosyltransferase in human uterine endometrial cancer-derived cells as measured by enzyme-linked immunosorbent assay and thin-layer chromatography-immunostaining.

Authors:  J Yoshiki; K Kubushiro; K Tsukazaki; Y Udagawa; S Nozawa; M Iwamori
Journal:  Jpn J Cancer Res       Date:  1997-07

Review 8.  Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine.

Authors:  Christine Yee; Kristie-Ann Dickson; Mohammed N Muntasir; Yue Ma; Deborah J Marsh
Journal:  Front Bioeng Biotechnol       Date:  2022-02-10

9.  Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.

Authors:  Eniko Papp; Dorothy Hallberg; Gottfried E Konecny; Daniel C Bruhm; Vilmos Adleff; Michaël Noë; Ioannis Kagiampakis; Doreen Palsgrove; Dylan Conklin; Yasuto Kinose; James R White; Michael F Press; Ronny Drapkin; Hariharan Easwaran; Stephen B Baylin; Dennis Slamon; Victor E Velculescu; Robert B Scharpf
Journal:  Cell Rep       Date:  2018-11-27       Impact factor: 9.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.